532872 Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹209.40 |
| 52 Week High | ₹474.00 |
| 52 Week Low | ₹189.45 |
| Beta | 0.83 |
| 11 Month Change | 0.26% |
| 3 Month Change | -7.16% |
| 1 Year Change | -24.51% |
| 33 Year Change | -13.88% |
| 5 Year Change | 34.19% |
| Change since IPO | 140.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532872 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 6.8% | 0.8% | 2.9% |
| 1Y | -24.5% | 42.1% | 28.9% |
Return vs Industry: 532872 underperformed the Indian Pharmaceuticals industry which returned 43.3% over the past year.
Return vs Market: 532872 underperformed the Indian Market which returned 28.6% over the past year.
Price Volatility
| 532872 volatility | |
|---|---|
| 532872 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532872 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532872's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 409 | Anilkumar Raghavan | www.sparc.life |
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| 532872 fundamental statistics | |
|---|---|
| Market cap | ₹67.83b |
| Earnings (TTM) | -₹4.09b |
| Revenue (TTM) | ₹600.85m |
112.9x
P/S Ratio-16.6x
P/E RatioIs 532872 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532872 income statement (TTM) | |
|---|---|
| Revenue | ₹600.85m |
| Cost of Revenue | ₹376.39m |
| Gross Profit | ₹224.47m |
| Other Expenses | ₹4.31b |
| Earnings | -₹4.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.59 |
| Gross Margin | 37.36% |
| Net Profit Margin | -680.16% |
| Debt/Equity Ratio | -114.7% |
How did 532872 perform over the long term?
See historical performance and comparison